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T reatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces programmed cell death in a wide range of transformed cells both in vitro and in vivo without producing significant toxicity to normal cells. [1] [2] [3] This unique property makes TRAIL an attractive candidate for cancer therapy. However, a significant proportion of breast cancer cell lines is resistant to TRAIL-induced apoptosis. 4, 5 Resistance to TRAIL is likely mediated by a number of mechanisms. Binding of TRAIL to its functional receptors, DR4 and DR5, can be decreased due to TRAIL sequestering by nonfunctional decoy receptors that do not transmit an apoptotic stimulus. [6] [7] [8] [9] Mutational loss of expression of DR4 and DR5, allelic loss or methylation of the genes has also been observed in several neoplasms including metastatic breast cancers. [10] [11] [12] [13] [14] Death receptor signaling can be counteracted at multiple levels by enhanced expression and/or activity of inhibitory molecules, including FLIP, [15] [16] [17] [18] bcl-2 and bcl-XL, [19] [20] [21] members of IAP family, 22 Akt 23, 24 and NFkB. 4, 25 The resultant sensitivity to TRAIL is thus determined by a balance of the apoptotic signal, transmitted by death receptors, and prosurvival action of inhibitors of the extrinsic pathway of apoptosis. Therefore, we hypothesized that overexpression of a death receptor will tip this balance towards programmed cell death and will thus sensitize breast cancer cells to TRAIL. In this report, we show that expression of DR4 from a strong CMV promoter efficiently kills breast cancer cells even in the absence of exogenous TRAIL. When targeted to cancer cells by a relatively weak hTERT promoter, DR4 alone induces apoptosis less efficiently, but sensitized cells to the effects of soluble TRAIL.
Materials and methods

Cell lines and reagents
Human breast cancer cell lines MCF-7, CAMA-1, HCC 1937, MDA-MB-231, T-47D and AU 565 were obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were maintained in RPMI 1640 (T-47D, AU-562 and HCC 1937), a-MEM (MCF-7 and CAMA-1) or Leibovitz's-15 (MDA-MB-231) medium with 10% FBS, penicillin (100 U/ml) and streptomycin (100 mg/ml) at 371C. Except for MDA-MB-231, all cell lines were grown in humidified atmosphere with 5% CO 2 
Plasmids and cloning
pRL-TK and pSV40-b-galactosidase were purchased from Promega. DR4 cDNA in pCMV-Sport6 vector was obtained from ATCC Mammalian Gene Collection (BC012866). An EcoRI/ApoI DR4-containing fragment was subcloned into EcoRI sites of pcDNA3.1 and IRES2-EGFP to produce CMV-DR4 and IRES-DR4, respectively. pp76, containing luciferase gene under control of hTERT promoterÀ1375 relative to transcription start site in pGL3 Basic vector, was kindly provided by Dr Kyo. It was cut on MluI/PstI, blunt-ended and reclosed to delete XbaI site. Luciferase activity of the resultant construct, tested in our panel of breast cancer cell lines, did not differ from that of pp76. The XbaI/HindIII fragment containing luciferase gene was than replaced by XbaI/HindIII fragment containing DR4, isolated from CMV-DR4, to produce hTERT-DR4. To produce CMV promoterguided luciferase, luciferase gene was cut out of pGL3-Basic on HindIII/XbaI, cloned into HindIII/XbaI site of pcDNA3.1 and called CMV-Luc. To incorporate luciferase gene into IRES-EGFP2 vector, pGL3-Basic was cut on XbaI, blunt-ended and cut on NheI. The resultant luciferase-containing fragment was cloned into the SmaI/ NheI site of IRES2-EGFP vector to produce IRES-Luc.
Transfections and reporter assays
Transient transfections were performed with FuGENE 6 transfection reagent as per the manufacturer's protocol. Briefly, 5 Â 10 4 cells/well were plated in 24-well plates and incubated overnight. For promoter activity studies, hTERT-or CMV-firefly luciferase promoter construct was cotransfected with pRL-TK (Promega) at a ratio of 1:1 into duplicate wells. Cells were harvested 36 hours later and dual luciferase assay was performed using Promega Dual-Luciferase Reporter Assay System as per the manufacturer's protocol. Results are presented as a ratio of Firefly/Renilla luciferase activity. For cell killing experiments, 5 Â 10 4 cells in duplicate wells were cotransfected with a DR4-containing construct or a corresponding vector together with the pSV40-b-galactosidase reporter gene at a ration of 1:1. When indicated, soluble TRAIL was added to cultures at the time of transfection. b-Galactosidase activity was tested with a luminescent bgal detection kit 36 hours later. Relative cell survival was measured as a percent of b-galactosidase reporter activity in DR4 vs. vector-transfected cultures.
MTS cytotoxicity assay
Cells were plated 2 Â 10 4 /well in triplicate wells and incubated overnight. Serial dilutions of soluble TRAIL in Hank's balanced salt solution (HBSS) were added to the wells and cells were incubated for additional 36 hours. Cytotoxicity was assessed using CellTiter 96 Non-Radioactive Cell Proliferation Assay and medium background was subtracted. Results are presented as percent of HBSStreated control.
Annexin V determination
In total, 1 Â 10 6 cells were plated per 60 mm dish and cultured overnight. Cells were then left untreated or treated with soluble TRAIL (100 ng/ml) and incubated for additional 36 hours. Cells were then trypsinized and washed with 1 Â Binding Buffer. For each condition, half of the cell suspension was left untreated and another half was incubated for 15 minute at room temperature in the dark with Annexin V. Immediately after staining, cells were analyzed by flow cytometry.
Western blotting
Exponentially growing cells were lysed in lysis buffer (62.5 mM Tris-HCL, pH 6.8, 2% SDS, 1 mM phenylmethylsulfonyl fluoride (PMSF). Cell lysates were sonicated and protein concentrations were determined using Bio-Rad protein assay reagent. In all, 25 mg of whole-cell protein lysate from each sample was diluted in 25 ml of SDS loading buffer (4% SDS, 2% glycerol, 0.01% bromphenol blue and 125 mM Tris-HCL,pH 6.8) incubated 5 minutes at 981C, 5 minutes on ice and spun down at maximal speed in a microcentrifuge at room temperature. Proteins were resolved on SDS polyacrylamide gel and transferred to PVDF membrane. Membranes were blocked for 1 hour in 5% nonfat dry milk, 10 mM TrisHCl pH 7.5, 150 mM NaCl, 0.1% Tween 20 and incubated for 2 hours with primary antibodies diluted in blocking buffer. Membranes were then washed four times with washing buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) and incubated for 1 hour with horseradish peroxidase-labeled secondary antibody in blocking buffer.
RNase protection assay
RNase protection assays were performed with hApo Multi-Probe Template Sets (BD Biosciences) according to the manufacturer's protocol. Briefly, 5 mg of total RNA, collected from each of the exponentially growing cell lines, was hybridized overnight to 32 P-labeled riboprobes, produced on the templates included in the sets. Unhybridized probes were digested by RNaseA. Probes, DR4 efficiently kills breast cancer cells I Kazhdan and RA Marciniak protected by hybridization to cellular RNA, were resolved on 5% sequencing gel and detected by autoradiography. Expression of the apoptosis-related genes was normalized to that of housekeeping genes (GAPDH).
Results
CMVpromoter/enhancer-guided DR4 efficiently kills breast cancer cells
To evaluate the potential of DR4 overexpression in treating breast cancer, we assembled a panel of six breast cancer cell lines. These cell lines differ in expression of, or harbor mutations in, genes that are considered relevant for the prognosis and management of the disease: estrogen receptor (ER), Her2/neu and p53. Thus, these cell lines partially reflect the genetic heterogeneity present in primary breast cancer. When known, other significant alterations (c-myc amplification, BRCA1 mutation) were also included. The following cell lines were used: MCF-7 (ER positive, Her2/neu negative, p53 wild type); MDA-MB-231 (ER negative, Her2/neu negative, p53 mutant); T-47D (ER positive, Her2/neu amplified, p53 mutant); HCC 1937 (ER negative, Her2/neu negative, p53 mutant, BRCA1 mutation); AU 565 (ER negative, Her2/neu amplified and overexpressed, p53 mutant, c-myc amplified); CAMA-1 (ER positive, Her2 positive, p53 status unknown, c-myc amplified).
To assess the killing efficiency of DR4, we employed two approaches. In the first, all six breast cancer cell lines were cotransfected with a b-galactosidase reporter gene together with DR4 under the control of the CMV promoter/enhancer (CMV-DR4) or empty vector. This approach is based on the observation that expression of a ''killer gene'' in transfected cells results in cell death and thus prevents accumulation of the b-galactosidase reporter protein. Survival is measured as reduction of bgalactosidase activity in DR4-transfected compared to vector-transfected cultures (Fig 1) . Introduction of CMV-DR4 decreased cell viability below 5% of the vectortransfected cells in five out of six cell lines in the absence of exogenous TRAIL (Fig 1a) . In the relatively resistant MCF-7 cell line, cell survival ranged between 16 to 21%. Addition of TRAIL further decreased cell survival to below 1% in AU-562, CAMA-1 and HCC 1937 cells, but had no effect in MCF-7, MDA-MB-231 and T47D cell lines (Fig 1b) .
As an alternative method to estimate the effect of DR4 expression on cell survival, DR4 or luciferase (as a control) was cloned into vector pIRES2-eGFP (IRES-DR4 and IRES-Luc, respectively). Thus, the reporter and the ''killer'' gene did not have to be cotransfected; they were present on the same construct and translated from the same bicistronic mRNA. Cell killing was manifested by the decrease in GFP-positive cells in IRES-DR4-transfected cultures as compared with cultures transfected with IRES-Luc. To confirm that overexpression of DR4 killed cells via induction of apoptosis, transfected cell population was also incubated with AnnexinV-PE. As demonstrated in Table 1 , when the CAMA-1 cell line is transiently transfected with the IRES-Luc construct, 19.7% of cells expressed GFP 48 hours after transfection. In IRES-DR4-transfected populations, the proportion of GFP-positive cells was significantly decreased. This decrease in viable, GFP-positive cells correlated with the increase in apoptotic, Annexin V-positive cells in the transfected population. We did not see a significant number of GFP þ AnnexinV þ cells. This is most likely To demonstrate that increased expression of DR4 was capable of killing TRAIL-resistant cells, we tested sensitivity of the cell lines to soluble TRAIL. Cells were treated with increasing concentrations of recombinant TRAIL or PBS control for 48 hours and cell viability was tested by MTS assay. Only two cell lines, MDA-MB-231 and CAMA-1, showed a significant TRAIL-dependent reduction of viability (Fig 2a) . In MDA-MB-231 cells, TRAIL had a biphasic effect, decreasing cell viability at higher doses while increasing cell proliferation and/or survival at lower concentrations. This prosurvival effect may be explained by the observation that low doses of TRAIL are sufficient to activate of NF-kB, but insufficient to induce apoptosis. 26, 27 Further increase of TRAIL concentrations did not enhance cell death in any of the cell lines tested (data not shown). To confirm results obtained in MTS test, cells were incubated with 100 ng of TRAIL for 36 hours, stained for Annexin V and analyzed by flow cytometry (Fig 2b) . The results were in general agreement with the data obtained by MTS test, although MCF-7 and HCC 1937 cells, completely resistant to TRAIL-induced apoptosis by MTS, both showed approximately 17% increase in Annexin V staining. Thus, although only two breast cancer cell lines were sensitive to soluble TRAIL, all of them were efficiently destroyed by DR4.
Killing efficiency of hTERT-guided DR4 in breast cancer lines
The efficiency of DR4 in killing cancer cells irrespective to their sensitivity to TRAIL suggested that DR4 might be equally toxic to normal cells. To minimize potential toxicity, we targeted expression of this gene to telomerasepositive cancer cells. First, we examined hTERT promoter activity in breast cancer cells and compared it to the activity of CMV (Fig 3) . In three cell lines, CAMA-1, AU 565 and MCF-7, hTERT promoter activity was relatively high, although significantly (120-450 times) lower than that of the CMV promoter/enhancer (Fig 3a, b) .
We next assessed the killing efficiency of hTERT promoter-guided DR4 (hTERT-DR4). In all cell lines examined, hTERT-DR4 alone was significantly less effective than CMV-DR4. Among three cell lines with relatively high hTERT promoter activity, two (CAMA-1 and AU 565) demonstrated an average of 36 and 63% cell survival, respectively (Fig 4a) . Addition of TRAIL further decreased survival of CAMA-1 cells to an average of 7% and AU 565 cells to an average of 36%. MCF-7 cells, which were relatively resistant to high levels of DR4 expressed from a CMV promoter, did not show significant cell death when transfected with hTERT-DR4, with or without addition of exogenous TRAIL.
In cell lines with relatively low hTERT promoter activity, hTERT-DR4 did not cause significant decrease in cell survival when used alone (Fig 4b, stripped bar) . When hTERT-DR4 was used in combination with TRAIL (white bar), it did not increase cell death over that achieved by TRAIL alone (black bar).
Expression of genes involved in TRAIL-induced apoptosis in breast cancer cells
The data presented indicates that the killing efficiency of hTERT-DR4 depends on two factors: the activity of hTERT promoter and the resistance to DR4-induced apoptosis. To begin assessment of the mechanisms that may contribute to resistance to DR4, we compared expression of genes involved in TRAIL-mediated apoptosis in the relatively DR4-resistant MCF-7 cells and the five DR4-sensitive cell lines.
The levels of DR4 and DR5 proteins in MCF-7 cells were not significantly lower than in other cell lines under study (Fig 5a) . MCF-7 cells did not express TRAIL, but this was also true for three out of five sensitive cell lines. MCF-7 cells did express elevated levels of two splice variants of the apoptosis-inhibiting protein FLIP -FLIP L and FLIPs.
MCF-7 cells are deficient in caspase 3. 28 This deficiency could contribute to their relative inability to undergo apoptosis in response to DR4. However, this deficiency might not be restricted to MCF-7 cell line, as recent evaluation of caspase 3 mRNA and protein in primary breast tumors demonstrated lack of expression in 75% of the samples. 29 To determine whether the absence of caspase 3 expression in MCF-7 cells was unique, we evaluated expression of caspases in our panel of breast cancer cell lines by Western blotting. No caspase 3 protein was detected in MCF-7 cells, while all other cell lines expressed readily detectable level of protein (Fig 5b) . Of note, MCF-7 cells express caspase 7, a member of the caspase 3 subfamily, which could substitute for caspase 3 in execution of apoptosis (Fig 5b) . We also performed screening of expression of other caspase family members by RNase protection assay. There was no difference in expression of caspases 2, 4, 8 and 10A between MCF-7 and the DR4-sensitive cell lines. Caspase 6 expression was DR4 efficiently kills breast cancer cells I Kazhdan and RA Marciniak lower in MCF-7 cells, but the significance of this finding is uncertain (data not shown).
Other mediators of apoptosis that have implicated in resistance to TRAIL include members of the bcl 2 and IAP families. Given a large number of genes in each family, we initially screened expression of 22 bcl 2 and IAP family members by RNAse protection. [19] [20] [21] No correlation of DR4 resistance with mRNA levels was identified for bcl-2 family members Bcl-XL, bclw and mcl-1, as well as for IAP family members XIAP, survivin, c-IAP 1 and 2 and NIAP (data not shown). bcl 2 mRNA was expressed at a higher level in MCF-7 as compared to the DR4-sensitive cell lines (data not shown). Overexpression of bcl 2 was further confirmed by Western blotting (Fig 5b) . As expression of Bcl-XL was specifically implicated in TRAIL resistance, 21 we confirmed the absence of correlation of Bcl-XL expression and DR4 resistance by Western blot (Fig 5b) .
Discussion
The unique ability of TRAIL to selectively kill tumor cells of diverse origin has attracted much attention over the past years. 1, 2 However, several studies demonstrated that DR4 efficiently kills breast cancer cells I Kazhdan and RA Marciniak a significant proportion of breast cancer cell lines are resistant to soluble TRAIL. In this study, we attempted to overcome TRAIL resistance by overexpression of the TRAIL receptor, DR4. We hypothesized that overexpression of a functional death receptor will enhance the death stimulus sufficiently to counterbalance the activity of prosurvival pathways and thus will tip the balance towards apoptosis. Indeed, introduction of DR4 under strong CMV promoter efficiently killed all breast cancer cell lines irrespective to their sensitivity to soluble TRAIL. MCF-7 cells were somewhat more resistant than the other cell lines (average relative cell survival in CMV-DR4-expressing cells was 18.3 vs. 0.75-4.4% survival obtained with other cells). The ability of DR4 to kill cells in the absence of external TRAIL could be explained by two mechanisms: (1) cell lines under study themselves produce TRAIL, which then interacts with DR4; (2) high intracellular concentrations of DR4 lead to its ligandindependent oligomerization. As only two cell lines expressed detectable levels of TRAIL on Western blot, the first explanation is unlikely to be true. A role of ligand-independent receptor oligomerization at high concentrations is also suggested by the fact that cytotoxicity of CMV-guided DR4 was not significantly enhanced by addition of exogenous TRAIL. Ligand-independent oligomerization was previously demonstrated for another death receptor, Fas. 30, 31 For cancer gene therapy applications, strong cytotoxicity, exhibited by DR4 overexpression, required targeting. For this purpose, we used the promoter of the hTERT gene, which has been shown to be selectively active in cancer cells, [32] [33] [34] [35] to drive DR4 expression. The main disadvantage of the majority of the currently available tumor-specific promoters, including hTERT, is relative low promoter strength. Indeed, among breast cancer cell lines tested, only three (CAMA-1, AU 565 and MCF-7) had comparatively high hTERT promoter activity. In the cell lines with high hTERT promoter activity, the level of expression of the Luciferase reporter driven by the hTERT promoter was still two orders of magnitude lower than that of CMV promoter. In two of these cell lines (CAMA-1 and AU 565), hTERT-DR4 induced cell death. In accord with the promoter activity studies, the degree of cell killing by hTERT-DR4 in these cell lines was lower than that induced by CMV-DR4. However, when cells were treated with a combination of hTERT-DR4 and TRAIL, a significant increase in cell killing was observed. In both cases, the combined effect of hTERT- Figure 3 Activity of hTERT promoter in breast cancer cell lines. (a) Evaluation of hTERT promoter activity. Cells in duplicate wells were cotransfected with phTERT and pRL-TK plasmids at a ratio of 1:1. Dual luciferase assay was performed 36 hours later. The data are presented as a ratio of hTERT-guided firefly luciferase activity to Renilla luciferase activity and represents an average of at least three independent experiments. (b) hTERT promoter activity is significantly lower than that of CMV promoter in breast cancer cells. Cells were transfected with pRL-TK together with either phTERT or CMVLuc construct (in which firefly luciferase is guided by CMV promoter) as described above. The data is presented as a ratio of hTERTguided firefly luciferase activity to RL activity. Figure 4b ), introduction of hTERT-DR4 alone did not cause significant cell death (striped bar). When hTERT-DR4 was combined with TRAIL (white bar), it did not increase toxicity over TRAIL alone in these cell lines (black bar).
MCF-7 cells were not affected by either hTERT-DR4 alone or by the combination of hTERT-DR4 with TRAIL, despite comparatively high hTERT promoter activity. These cells were also relatively resistant to CMV-DR4, with or without addition of soluble TRAIL. To begin identifying the mechanisms of their resistance, we compared expression of the members of several families of apoptotic regulators between MCF-7 cells and cell lines sensitive to DR4 overexpression.
Among the panel of apoptotic regulators tested, two genes, bcl-2 and FLIP, were expressed at a higher level in MCF-7 cells as compared to the DR4-sensitive cell lines. bcl-2 and FLIP have been shown to suppress TRAILinduced apoptosis 18, 20, 21, 36, 37 and are good candidates for DR4-resistance genes. Expression of Bcl-XL, another bcl-2 family member implicated in TRAIL resistance, 19, 21 did not show correlation with resistance to DR4. There was also no correlation between DR4 resistance and expression of caspases, IAP and other bcl-2 family members.
In our panel of cell lines, MCF-7 was the only line that lacked expression of caspase 3. It has been demonstrated that, despite the presence of functional effector caspase 7, apoptotic response to some stimuli, including staurosporine, VP-16 38 and photodynamic therapy, 39 was delayed or diminished in this cell line. Reconstitution of caspase 3 expression enhanced apoptosis induced by staurosporine and chemotherapeutic agents. 29, 38 These data suggest that caspase 3 deficiency could at least partially account for resistance of MCF-7 cells to DR4. On the other hand, apoptosis induced by overexpression of the proapoptotic bcl-2 family member Bak was not impaired in MCF-7 cells as compared to the caspase 3-expressing HeLa cells. 
